Abstracts tagged "Lupus"

Abstract Number: 688 • 2014 ACR/ARHP Annual Meeting
Corticosteroids in Early Treatment Pathways in SLE
John G. Hanly¹, Amyn Sayani², Steve Doucette³, Sandra Iczkovitz² and Jorge Alfonso Ross², ¹Division of Rheumatology, Dalhousie University and Capital Health, Halifax, NS, Canada, ²Medical Affairs, GlaxoSmithKline, Mississauga, ON, Canada, ³Dalhousie University and Capital Health, Halifax, NS, Canada
Background/Purpose: The treatment algorithm for patients with new onset systemic lupus erythematosus (SLE) is more variable than that for other rheumatic diseases (e.g. rheumatoid arthritis).…
Abstract Number: L23 • 2014 ACR/ARHP Annual Meeting
Humoral Immune Response to Pneumococcal Polysaccharide Vaccine in SLE Patients on Immunosuppressive Therapy: Assessment of Serotypes without Protective Antibody Levels
Rodrigo Poubel V. Rezende¹, Francinne M. Ribeiro¹, Luis Eduardo C. Andrade², Carlos Roberto M. Gayer³, Elisa M. N. Albuquerque¹ and Evandro Mendes Klumb¹, ¹Rheumatology, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ²Fleury Laboratories, Sao Paulo, Brazil, ³Department of Biochemistry, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil
Background/Purpose: Previous works assessing antibody response to pneumococcal polysaccharide vaccine (PPV) in systemic lupus erythematosus (SLE) relied exclusively on the quantitative increase in antibody titers…
Abstract Number: 2676 • 2014 ACR/ARHP Annual Meeting
The E3 Ligase Casitas B Lineage Lymphoma b (Cbl-b) Modulates Peripheral Regulatory T Cell Function Via p27^kip1in Patients with Systemic Lupus Erythematosus
Diana Gómez-Martín¹, Jorge Romo-Tena², Javier Merayo-Chalico³, Ana Barrera-Vargas¹ and Jorge Alcocer-Varela¹, ¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico city, Mexico, ³Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: The interplay between effector and regulatory T cells (Tregs) is a key element among peripheral tolerance mechanisms in Systemic Lupus Erythematosus (SLE). Resistance to…
Abstract Number: 1605 • 2014 ACR/ARHP Annual Meeting
Elevated Regulatory Mediators and Interferon Gamma Associated Responses, but Not Interferon Alpha, BLyS or IP-10, Accompany High-Titer Anti-Ro Autoantibodies in Asymptomatic Mothers of Children with Neonatal Lupus
Peter M. Izmirly¹, Robert M. Clancy², Melissa Munroe³, Sara Rasmussen², Amit Saxena^2,4, Jose U. Scher², Aikaterini Thanou⁵, Stan Kamp⁶, Joan T. Merrill⁷, Jill P. Buyon² and Judith James⁸, ¹Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ²Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ³Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Rheumatology, New York University School of Medicine, New York, NY, ⁵Arthritis and Clinical Immunology Reseach Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁷Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁸Arthritis & Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Mothers of children with neonatal lupus offer a unique opportunity to study the drivers and consequences of autoantibody production in the absence of ongoing…
Abstract Number: 687 • 2014 ACR/ARHP Annual Meeting
Effect of Corticosteroid Use By Dose on the Risk of Developing Organ Damage over Time in Systemic Lupus Erythematosus—the Hopkins Lupus Cohort
Sarah Al Sawah¹, Xiang Zhang¹, Baojin Zhu¹, Laurence S. Magder², Shonda A Foster¹, Noriko Iikuni¹ and Michelle Petri³, ¹Eli Lilly and Company, Indianapolis, IN, ²Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD, ³Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Reduction of corticosteroid dose remains an important goal in the management of systemic lupus erythematosus (SLE). Current standard of care in SLE relies heavily…
Abstract Number: 2671 • 2014 ACR/ARHP Annual Meeting
Impact of Glucocorticoid Dose on Maternal and Fetal Outcomes in Lupus Pregnancies
Dafhne Miranda¹, Miguel A. Saavedra², Eduardo Gomez³, Alberto Daniel Rocha Muñoz⁴, Jorge Gaspar Ramos⁵ and Luis Javier Jara⁶, ¹Rheumatology, Rheumatology Unit, Hospital de Especialidades. Centro Médico La Raza, IMSS, Distrito federal, Mexico, ²Rheumatology, Hospital de Especialidades Centro Médico La Raza, IMSS, Mexico City, Mexico, ³Institute for Research in Rheumatology and Musculoskeletal System, Guadalajara, Mexico, ⁴Institute for Research in Rheumatology and Musculoskeletal System, Guadalajara, Jalisco, Mexico, ⁵Rheumatology Unit, Hospital de Especialidades. Centro Médico La Raza, IMSS, Distrito federal, Mexico, ⁶Direction of Education and Research in health, Instituto Mexicano del Seguro Social, D.F., Mexico
Background/Purpose Lupus flares during pregnancy can be treated with short courses of low to moderate doses of glucocorticoids (GCs). GCs are associated with several maternal…
Abstract Number: 1311 • 2014 ACR/ARHP Annual Meeting
Lupus Nephritis in Mexican Children
María del Rocío Maldonado-Velázquez¹, Enrique Faugier¹, Fernando Garcia-Rodriguez², Paola Lara¹, Angel Flores¹, Javier Tomala-Haz¹ and Diego Salinas-Encinas¹, ¹Hospital Infantil de Mexico Federico Gomez, Mexico City, Mexico, ²Rheumatology, Hospital Infantil de Mexico Federico Gomez, Mexico City, Mexico
Background/PurposeIncidence and disease pattern of childhood-onset systemic lupus erythematosus (SLE) is reported to differ among ethnic groups. Lupus nephritis (LN) strongly affects the outcome in…
Abstract Number: 683 • 2014 ACR/ARHP Annual Meeting
Impact of Lupus on Work Productivity in Patients and Caregivers: Findings from a Cross-Sectional Online Survey in the United States
Sarah Al Sawah¹, R Paola Daly², Shonda Foster¹, April Naegeli¹, Katy Benjamin³, Helen Doll³, Greg Bond³, Olga Moshkovich³ and Graciela Alarcón⁴, ¹Eli Lilly and Company, Indianapolis, IN, ²Lupus Foundation of America, Inc., Washington, DC, ³ICON PRO, Bethesda, MD, ⁴University of Alabama Birmingham, Birmingham, AL
Background/Purpose Lupus imposes a substantial burden on patients’ work productivity1; however, little is known about its impact on the work productivity of those caring for…
Abstract Number: 2644 • 2014 ACR/ARHP Annual Meeting
Carotid Intima-Media Thickness and Plaque in Mexican Mestizos with Systemic Lupus Erythematosus: A Case-Control Study
Iris J. Colunga-Pedraza¹, Dionicio A. Galarza-Delgado¹, Alberto Cardenas-de La Garza¹, Ana L. Sanchez-Nuñez¹, Samantha L. Segarra-Linares¹, Rocío A. Carrillo-Palacios¹, David Vega-Morales¹, Fernando Góngora-Rivera² and Mario Alberto Garza-Elizondo¹, ¹Rheumatology, Hospital Universitario UANL, Monterrey, Mexico, ²Neurology., Hospital Universitario UANL, Monterrey, Mexico
Background/Purpose Systemic lupus erythematosus (SLE) patients are at risk of premature cardiovascular disease (CVD). The specific reason of this situation is still debatable. Subclinical atherosclerosis…
Abstract Number: 1297 • 2014 ACR/ARHP Annual Meeting
Safety and Efficacy of Rituximab in Pediatric Lupus and Other Rheumatic Diseases
Ajay Tambralli¹, Timothy Beukelman², Randy Q. Cron² and Matthew L. Stoll², ¹Medicine, University of Rochester, Rochester, NY, ²Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Rituximab (RTX) is a chimeric monoclonal antibody that specifically targets CD20 positive B cells and is used successfully for a variety of pediatric rheumatologic…
Abstract Number: 674 • 2014 ACR/ARHP Annual Meeting
A Novel Strategy to Identify and Evaluate Approved Drugs and Treatments for Repositioning As Therapies for Systemic Lupus Erythematosus (SLE)
Peter E. Lipsky, Matthew Ryals, Jacob Smearman, Victoria Soler and Amrie Grammer, AMPEL BioSolutions, Charlottesville, VA
Background/Purpose: Development of new SLE treatments has been slow with only one new treatment approved in the past half century. One way to increase the…
Abstract Number: 2643 • 2014 ACR/ARHP Annual Meeting
Angiogenic and Antiangiogenic Factors in Patients with Systemic Lupus Erythematosus
Guilherme Ramires de Jesus¹, Camila Souto Oliveira², Flavia Cunha dos Santos³, Nilson Ramires de Jesus³, Luis Cristovao Porto⁴, Roger A. Levy⁵ and Evandro Mendes Klumb⁶, ¹Department of Obstetrics, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ²Rheumatology, Hospital Universitario Pedro Ernesto, Rio de Janeiro, Brazil, ³Obstetrics, Hospital Universitario Pedro Ernesto, Rio de Janeiro, Brazil, ⁴Immunology, Hospital Universitario Pedro Ernesto, Rio de Janeiro, Brazil, ⁵Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ⁶Rheumatology, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil
Background/Purpose SLE mainly affects young women and pregnancy in these patients has significant morbidity and mortality. Clinical and laboratory findings in lupus nephritis are similar…
Abstract Number: 1213 • 2014 ACR/ARHP Annual Meeting
Absence of Hormone Responsive Estrogen Receptor Alpha Reduces the Activation of Plasmacytoid Dendritic Cells in Lupus Prone Mice
Jennifer L. Scott¹, Melissa A. Cunningham², Osama S. Naga³, Jackie G. Eudaly³, Jena R. Wirth⁴ and Gary S. Gilkeson⁵, ¹Microbiology and Immunology, Medical University of South Carolina, Charleston, SC, ²Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, ³Medicine/Rheumatology, Medical University of South Carolina, Charleston, SC, ⁴Med/Rheumatology, MUSC, Charleston, SC, ⁵Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC
Background/Purpose Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease that affects women at a 9 to 1 ratio compared to men. To further understand…
Abstract Number: 668 • 2014 ACR/ARHP Annual Meeting
Evolution of Patients with Systemic Lupus Erythematous Treated with Belimumab in Clinical Practice Settings
Josefina Cortes¹, Carlos Marras², Jose Luis Andreu³, Jaime Calvo-Alen⁴, Angel M. Garcia-Aparicio⁵, Elvira Diez Alvarez⁶, Carlos Coronell⁷, Elena Morejon⁷, Alessandra Perna⁸, Volker Koscielny⁸ and Josep Ordi-Ros¹, ¹Internal Medicine, Vall d´Hebron Hospital, Barcelona, Spain, ²Rheumatology, Virgen de la Arrixaca Hospital, Murcia, Spain, ³Rheumatology, Puerta de Hierro Universitary Hospital, Madrid, Spain, ⁴Rheumatology Division, Sierrallana Hospital, Torrelavega, Spain, ⁵Rheumatology, Virgen de la Salud Hospital, Toledo, Spain, ⁶Rheumatology, Leon Hospital, Leon, Spain, ⁷Medical Department, GlaxoSmithKline, Madrid, Spain, ⁸Medical Department, GlaxoSmithKline, Brentford, United Kingdom
Background/Purpose After the approval of belimumab for patients with systemic lupus erythematosus (SLE), the objective of this study is to describe the clinical outcomes associated…
Abstract Number: 2639 • 2014 ACR/ARHP Annual Meeting
Coronary-Artery Atherosclerosis in Males with Systemic Lupus Erythematosus
Juanita Romero-Díaz¹, Sergio Criales-Vera², Eric Kimura-Hayama², Roberto Ivan Acosta-Hernandez¹, Maricruz Dominguez-Quintana¹ and Jorge Sánchez-Guerrero³, ¹Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico, ²Radiology Department, Instituto Nacional de Cardiologia, Mexico City, Mexico, ³Rheumatology, Mount Sinai Hospital and University Health Network, Toronto Canada, Toronto, ON, Canada
Background/Purpose . Premature coronary-artery atherosclerosis is a major cause of morbidity and mortality in females with systemic lupus erythematosus (SLE), but little is known about the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.